Iratumumab: Difference between revisions
CSV import |
CSV import Tag: Reverted |
||
| Line 54: | Line 54: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Revision as of 15:28, 17 March 2025
| Iratumumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Iratumumab is a monoclonal antibody designed for the treatment of various forms of cancer. This drug functions as an immune system modulator, targeting specific cells within the body to inhibit the growth and spread of malignant cells.
Mechanism of Action
Iratumumab works by binding to a specific antigen on the surface of cancer cells. This binding can lead to the direct inhibition of cancer cell growth, as well as the induction of an immune response against the targeted cells. The exact mechanism of action may vary depending on the type of cancer being treated.
Clinical Uses
Iratumumab is under investigation for its potential use in the treatment of multiple types of cancer, including leukemia, lymphoma, and solid tumors. Clinical trials are ongoing to determine its efficacy and safety in these different settings.
Pharmacokinetics
Details on the pharmacokinetics of Iratumumab, such as absorption, distribution, metabolism, and excretion, are currently being studied in clinical trials.
Adverse Effects
As with any cancer therapy, Iratumumab may cause side effects, which can vary widely among patients. Common adverse effects associated with monoclonal antibodies include infusion reactions, fatigue, and immune-related effects. Specific side effects related to Iratumumab will be better understood as clinical trial data becomes available.
Development and Regulatory Status
Iratumumab is still in the development phase and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The outcomes of ongoing clinical trials will determine its path towards approval and its future in cancer therapy.
See Also
